RPG Life Sciences – Investor Presentation Summary
Key Operational Highlights
- API business operates from state-of-the-art facility in Navi Mumbai focused on high-value low-volume niche products
- External third-party sales of ~95.1 Cr INR in FY26 apart from captive sales to RPGLS formulations business
- Actis Generics manufacturing facility running at close to full capacity with expansion possibility
- Raghava Life Sciences has large installed capacity of 300 KL spread over 9 acres near Hyderabad
- Raghava portfolio includes 29 API molecules (22 commercialized, 7 under development)
Key drivers of operational performance:
- Focus on products insulated from price commoditization and Chinese competition
- Strong R&D focus with growing product pipeline
- Acquisition of backward-integrated manufacturing capabilities
- Secured regulatory approvals (WHO GMP, EU GMP, KDMF, CEP)
Segment-wise Performance
Not Specified
Financial Highlights
Not Specified
Geographical Revenue Split
Not Specified
Balance Sheet Snapshot
Not Specified
Capex & Cash Flow Health
Not Specified
Strategic & R&D Initiatives
- Subsidiariation of API business into RPG Active Pharma completed via Business Transfer Agreement (slump sale)
- Partnership with InvAscent, a pharma-centric PE firm with USD 850M+ AUM across 4 funds
- Acquisition of Actis Generics, a backward-integrated API manufacturer based in Vizag with anti-diabetic and cardiology portfolio
- Acquisition of Raghava Life Sciences with state-of-the-art facility near Hyderabad
- Supply Services and Transition agreement established for continuing captive sales and shared services
- Revenue and cost synergy potential between Actis, Raghava and RPGAP
- Plant revenue potential of about 200 Cr INR at full utilization levels for Raghava facility
Industry Trends & Business Environment
Not Specified
Management Commentary & Growth Outlook
- Partnership with InvAscent expected to yield benefits in product selection, M&A, customer connects, and cross-sell synergies
- Strong management team being established with CEO having experience at Teva, DRL, UPL and CXOs with strong industry pedigree
- Transaction provides access to marquee customer relationships
- Strategic readiness in all aspects for future growth
Transaction Timeline
- Investment and shareholders' agreement dated 29th July 2026 (pending closing)
- Share Purchase Agreement for Actis Generics dated 29th July 2026 (pending closing)
- Business Transfer Agreement for Raghava Life Sciences dated 02nd September 2026 (pending closing)